Ra Pharmaceuticals Inc (NASDAQ:RARX) saw unusually-high trading volume on Friday . Approximately 2,213,052 shares were traded during trading, an increase of 379% from the previous session’s volume of 461,860 shares.The stock last traded at $27.22 and had previously closed at $26.56.
RARX has been the subject of a number of analyst reports. Jefferies Financial Group upped their price objective on shares of Ra Pharmaceuticals to $40.00 and gave the company a “positive” rating in a research note on Monday, December 10th. SunTrust Banks upped their price objective on shares of Ra Pharmaceuticals to $35.00 and gave the company a “buy” rating in a research note on Tuesday, December 11th. BMO Capital Markets set a $34.00 price objective on shares of Ra Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, December 10th. Stifel Nicolaus initiated coverage on shares of Ra Pharmaceuticals in a research note on Friday, February 8th. They set a “buy” rating and a $55.00 price objective for the company. Finally, BidaskClub raised shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, December 8th. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company. Ra Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $36.50.
The company has a market cap of $881.87 million, a P/E ratio of -13.21 and a beta of 0.83.
Ra Pharmaceuticals (NASDAQ:RARX) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The company had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $2.50 million. As a group, equities research analysts predict that Ra Pharmaceuticals Inc will post -2.16 EPS for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the stock. Quantamental Technologies LLC bought a new stake in shares of Ra Pharmaceuticals during the 4th quarter worth $44,000. Legal & General Group Plc lifted its position in shares of Ra Pharmaceuticals by 57.7% during the 4th quarter. Legal & General Group Plc now owns 3,063 shares of the company’s stock worth $56,000 after buying an additional 1,121 shares during the last quarter. Federated Investors Inc. PA bought a new stake in shares of Ra Pharmaceuticals during the 3rd quarter worth $65,000. Great West Life Assurance Co. Can bought a new stake in shares of Ra Pharmaceuticals during the 4th quarter worth $63,000. Finally, Meeder Asset Management Inc. lifted its position in shares of Ra Pharmaceuticals by 62.8% during the 4th quarter. Meeder Asset Management Inc. now owns 5,311 shares of the company’s stock worth $96,000 after buying an additional 2,049 shares during the last quarter.
Ra Pharmaceuticals Company Profile (NASDAQ:RARX)
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Featured Story: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.